ArticleAIDS research and therapy2026
A revised neuropsychological test battery, CoCoBattery-Plus, for the diagnosis of HIV-associated neurocognitive disorders in Japan.
Article in AIDS research and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To diagnose HIV-associated neurocognitive disorders (HAND), several neuropsychological test batteries have been used in various studies and countries. In Japan, the Co-developing Comprehensive Neuropsychological Test Battery (CoCoBattery) was developed during a nationwide study conducted between 2014 and 2016 (the J-HAND study) to explore the prevalence of HAND and has been widely used thereafter. It consists of 14 tests covering eight key cognitive domains: language, attention/working memory, executive function, learning, memory, information-processing speed, visuospatial construction, and motor skills. However, some cases have been difficult to classify in terms of HAND severity due to the lack of subjective impairment assessments in CoCoBattery. Therefore, we added cognitive screening questions to CoCoBattery (CoCoBattery-Plus) and compared the results among 103 HIV-positive individuals. Using the original battery, 10 cases were diagnosed with HIV-associated dementia (HAD), 13 with mild neurocognitive disorder (MND), 39 with asymptomatic neurocognitive impairment (ANI), and 41 with no HAND. In contrast, using the new battery, four individuals who were previously unaware of cognitive impairment reported subjective complaints in response to the questions, leading to diagnostic changes: one case from ANI to HAD and three from ANI to MND. The final diagnoses were 11 HAD, 16 MND, and 35 ANI, corresponding to a reclassification rate of 3.9%. Subjective complaints are a crucial component in determining the severity of HAND, and we anticipate that CoCoBattery-Plus will enable more accurate HAND diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.